SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 2,520 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CFO George Cardoza sold 2,520 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $12,222.00. Following the sale, the chief financial officer directly owned 295,274 shares of the company’s stock, valued at $1,432,078.90. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Tuesday, April 7th, George Cardoza sold 2,413 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.88, for a total value of $11,775.44.
• On Thursday, March 19th, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $3,707.46.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded down $0.01 during trading hours on Wednesday, reaching $4.89. 64,929 shares of the company were exchanged, compared to its average volume of 188,371. The firm has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The stock has a 50-day moving average of $4.78 and a 200 day moving average of $4.68. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. As a group, research analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SOPH shares. BTIG Research reiterated a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim upped their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $54,000. Archon Capital Management LLC increased its position in shares of SOPHiA GENETICS by 3.4% during the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after purchasing an additional 14,342 shares during the period. Renaissance Technologies LLC increased its position in shares of SOPHiA GENETICS by 169.5% during the fourth quarter. Renaissance Technologies LLC now owns 83,000 shares of the company’s stock valued at $388,000 after purchasing an additional 52,200 shares during the period. Finally, Polen Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $102,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.